Rhumbline Advisers boosted its position in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 0.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,810 shares of the biopharmaceutical company’s stock after purchasing an additional 423 shares during the quarter. Rhumbline Advisers owned about 0.11% of Sucampo Pharmaceuticals worth $513,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SCMP. Virginia Retirement Systems ET AL bought a new stake in Sucampo Pharmaceuticals during the 1st quarter valued at $536,000. Bank of New York Mellon Corp lifted its holdings in shares of Sucampo Pharmaceuticals by 107.3% in the 1st quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the period. Texas Permanent School Fund lifted its holdings in shares of Sucampo Pharmaceuticals by 2.2% in the 2nd quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 398 shares during the period. State of Tennessee Treasury Department purchased a new stake in shares of Sucampo Pharmaceuticals in the 1st quarter worth $258,000. Finally, Royce & Associates LP lifted its holdings in shares of Sucampo Pharmaceuticals by 24.6% in the 1st quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock worth $10,714,000 after buying an additional 192,000 shares during the period. Institutional investors own 55.44% of the company’s stock.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 11.00 on Wednesday. Sucampo Pharmaceuticals, Inc. has a one year low of $9.30 and a one year high of $17.55. The stock’s market capitalization is $509.58 million. The stock has a 50 day moving average price of $11.67 and a 200-day moving average price of $10.73.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. During the same period in the prior year, the business earned $0.24 EPS. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. Analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.02 earnings per share for the current year.

In related news, insider Jones W. Bryan acquired 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the completion of the purchase, the insider now owns 4,700 shares in the company, valued at $49,820. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Insiders own 4.13% of the company’s stock.

A number of equities analysts have recently issued reports on SCMP shares. Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Mizuho lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $14.00 to $12.00 in a research note on Tuesday. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Maxim Group restated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Finally, BidaskClub lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $17.86.

TRADEMARK VIOLATION WARNING: “Rhumbline Advisers Grows Holdings in Sucampo Pharmaceuticals, Inc. (SCMP)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/04/rhumbline-advisers-grows-holdings-in-sucampo-pharmaceuticals-inc-scmp.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.